A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease

NCT07399704 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

GM2 Gangliosidosis
Niemann-Pick Type C Disease

Interventions

DRUG: AZ-3102

Sponsor

Azafaros A.G.